Metformin (Biguanide)

Brand names: Glucophage, Glucophage XR, Glumetza, Fortamet, Riomet

Drug Class & First-Line Status

Metformin is a biguanide and the most widely used antidiabetic medication worldwide. It is the preferred initial therapy for type 2 diabetes mellitus (T2DM) per ADA and AACE guidelines due to its efficacy, safety profile, low cost, and cardiometabolic benefits. - Goldman-Cecil Medicine, p. 983

Mechanism of Action

Hepatic gluconeogenesis inhibition (primary): Metformin enters hepatocytes via organic cation transporters and inhibits mitochondrial Complex I of the electron transport chain. This raises the AMP:ATP ratio, activating AMPK (AMP-activated protein kinase), which suppresses the key enzymes of gluconeogenesis (including fructose-1,6-bisphosphatase). The result is reduced hepatic glucose output.
Improved peripheral insulin sensitivity: Enhances insulin-stimulated glucose uptake in skeletal muscle, partly via AMPK-driven GLUT4 translocation.
Reduced intestinal glucose absorption: Modest decrease in GI glucose uptake.
No stimulation of insulin secretion - therefore it does not cause hypoglycemia as monotherapy.

Clinical Efficacy

Parameter	Effect
HbA1c reduction	1.0 - 1.5% (11-16 mmol/mol)
Body weight	Neutral to modest weight loss
Cardiovascular outcomes	Reduces CV events and death in obese T2DM (UKPDS)
Hypoglycemia risk	None as monotherapy

Goldman-Cecil Medicine, p. 985

Dosing

Adults (immediate release):

Start: 500 mg BID with meals (or 850 mg once daily)
Titrate: increase by 500 mg/week as tolerated
Maximum: 2550 mg/day in divided doses

Adults (extended release):

Start: 500 mg once daily with evening meal
Maximum: 2000-2500 mg/day

Children (10-16 years):

Start: 500 mg BID, titrate to max 2000 mg/day

All doses should be taken with meals to reduce GI side effects. - Harriet Lane Handbook, p. 1233

Adverse Effects

Effect	Notes
GI symptoms	Most common (~50%): nausea, bloating, diarrhea - dose-related, reduce by slow titration
Lactic acidosis	Rare but potentially fatal; risk elevated in renal impairment, hypoxia, hepatic disease
Vitamin B12 deficiency	Long-term use; monitor B12 annually; may worsen neuropathy

Contraindications & Precautions

eGFR < 30 mL/min/1.73 m²: Contraindicated (risk of lactic acidosis due to renal accumulation)
eGFR 30-45: Use with caution; reduce dose
Hepatic impairment: Contraindicated (impaired lactate clearance)
Iodinated contrast media: Hold metformin before/during procedures; restart 48 hours after if renal function is stable
CHF, metabolic acidosis, excessive alcohol use: Avoid
Surgical procedures: Temporarily hold

Drug interactions: Cimetidine, furosemide, nifedipine (OCT2/MATE inhibitors) can raise metformin levels. - Harriet Lane Handbook, p. 1234

Off-Label / Extended Uses

Polycystic ovary syndrome (PCOS): Improves insulin resistance, restores ovulation
Prediabetes / metabolic syndrome: Delays progression to T2DM
Gestational diabetes: Used in some guidelines (though insulin remains standard in many regions)
Clozapine-associated metabolic syndrome: Used to mitigate weight gain and insulin resistance
Anti-aging / longevity research: Active area of investigation (TAME trial)

Monitoring

Serum creatinine / eGFR: baseline and annually (or more often if at-risk)
HbA1c: every 3-6 months until stable, then every 6-12 months
Vitamin B12: baseline and every 1-2 years with long-term use
Fasting blood glucose

Recent Evidence (2024-2026)

Three recent systematic reviews highlight emerging aspects of metformin:

Exercise + metformin combination shows additive glycemic benefits in people with abnormal glycemic control (PMID: 39242178, Br J Sports Med, Dec 2024)
Dementia risk: A 2024 network meta-analysis found metformin may be associated with reduced dementia risk among antidiabetic agents (PMID: 39716328, Alzheimer's Res Ther)
Cardioprotective agents and dementia: A 2025 JAMA Neurology meta-analysis further evaluates metformin among cardioprotective agents for dementia risk reduction (PMID: 40193122)

Bottom line: Metformin remains the cornerstone of T2DM pharmacotherapy - effective, safe, affordable, and cardiometabolically beneficial. Its role may expand as evidence accumulates in aging, cancer prevention, and neurodegeneration.

This is a shared conversation. Sign in to Orris to start your own chat.